Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Introduction</h3><p>Prenatal maternal distress has a negative impact on the course of pregnancy, fetal development, offspring development and later psychopathologies. The study aimed to determine the extent to which the Coronavirus disease 2019 (COVID‐19) pandemic may aggravate pregnant women prenatal distress and psychiatric symptomatology.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Material and methods</h3><p>Two cohorts of pregnant volunteer women were evaluated, one that was recruited before the COVID‐19 pandemic (n=496) through advertisements in prenatal clinics in Quebec, Canada, from April 2018 to March 2020; the other (n=1258) was recruited online during the pandemic from April 2 to April 13 2020. Prenatal distress and psychiatric symptomatology were measured with the Kessler Distress Scale (K10), Post‐traumatic Checklist for DSM‐5 (PCL‐5), Dissociative Experiences Scale (DES‐II) and Positive and Negative Affect Schedule (PANAS).</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>The 1754 pregnant women (M<sub>age</sub>=29.27, SD=4.23) were between 4 and 41 gestational weeks (M=24.80, SD=9.42), were generally educated (91.3% had post‐high school training) and financially well‐resourced (85.3% were above the low‐income cut‐off). A multivariate analysis of covariance controlling for age, gestational age, household income, education and lifetime psychiatric disorders showed a large effect size (ES) in the difference between the two cohorts on psychiatric symptoms (Wilks' λ=0.68, <i>F </i><sub>6,1400</sub>=108.50, <i>p </i> < 0.001, partial η<sup>2</sup>= 0.32). According to post‐hoc analyses of covariance, the COVID‐19 women reported higher levels of depressive and anxiety symptoms (ES=0.57), dissociative symptoms (ES=0.22 and 0.25), symptoms of post‐traumatic stress disorder (ES=0.19), negative affectivity (ES = 0.96) and less positive affectivity (ES=0.95) than the pre‐COVID‐19 cohort. Women from the COVID‐19 cohort were more likely than pre‐COVID‐19 women to present clinically significant levels of depressive and anxiety symptoms [OR=1.94, <i>χ </i>2(1)=10.05, <i>p </i>=.002]. Multiple regression analyses indicated that COVID‐19 pregnant women having a previous psychiatric diagnosis or low income would be more prone to elevated distress and psychiatric symptoms. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions</h3><p>Pregnant women assessed during the COVID‐19 pandemic reported more distress and psychiatric symptoms than pregnant women assessed before the pandemic, mainly in the form of depression and anxiety symptoms. Given the harmful consequences of prenatal distress on mothers and offspring, the presently observed upsurge of symptoms in pregnant women calls for special means of clinical surveillance.</p></section>

Changes in prenatal cannabis‐related diagnosed disorders after the Cannabis Act and the COVID‐19 pandemic in Quebec, Canada

Changes in Cannabis-Attributable Hospitalizations Following Nonmedical Cannabis Legalization in Canada

Maternal, Fetal and Neonatal Outcomes Related to Recreational Cannabis Use during Pregnancy: Analysis of a Real-World Clinical Data Warehouse between 2010 and 2019

Prenatal Care Disruptions and Associations With Maternal Mental Health During the COVID-19 Pandemic

The Impact of COVID-19 on Maternal Mental Health During Pregnancy: A Comparison Between Canada and China Within the CONCEPTION Cohort

Opioid and Cannabis Use During Pregnancy and Breastfeeding in Relation to Sociodemographics and Mental Health Status: A Descriptive Study

Changes in Cannabis-Related Health Care Use in Alberta After Cannabis Legalization Between 2018 and 2022: A Population-Based Interrupted Time Series Study

Changes in Prenatal Cannabis Use Among Pregnant Individuals From 2012 to 2022

COVID-19 Infection and Medicines in Pregnancy in Canada

Elevated depression and anxiety symptoms among pregnant individuals during the COVID-19 pandemic

Prenatal distress, access to services, and birth outcomes during the COVID-19 pandemic: Findings from a longitudinal study

Association of psychiatric and substance use disorders with cannabis use and cannabis use disorder during early pregnancy in northern California

Uptrend in distress and psychiatric symptomatology in pregnant women during the coronavirus disease 2019 pandemic

The impact of prenatal maternal mental health during the COVID-19 pandemic on birth outcomes: two nested case-control studies within the CONCEPTION cohort

Is legal recreational cannabis associated with cannabis use during pregnancy, beliefs about safety, and perceived community stigma?

Cannabis exposure during pregnancy and perinatal outcomes: A cohort study

Psychosocial impacts, preventive behaviours, and concerns associated with the COVID-19 pandemic for pregnant and non-pregnant women: A matched analysis from the International iCARE Study

Understanding cannabis use and mental health difficulties in context with women's experiences of stressful events and social health issues in pregnancy: The aboriginal families study

Dietary changes among pregnant individuals compared to pre-pandemic: A cross-sectional analysis of the Pregnancy during the COVID-19 Pandemic (PdP) study

Estimating the effects of prenatal cannabis exposure on birth outcomes

The Relationship Between Rates of Cannabis Use and Covid-19 Infection Rates During the Pandemic: An Analysis of Canada's National Cannabis Survey